KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Heward J, Konali L, D'Avola A, Close K, et al. Blood 2021;138:370-381.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Heward J, Konali L, D'Avola A, Close K, et al. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood 2021;138:370-381.
PMID: 33786580